BOSTON, March 26 /PRNewswire/ -- Surface Logix Inc. announced today
that Jim Mahoney, President and Chief Executive Officer, will present an
update of the company's drug development pipeline at the 14th annual Future
Leaders in the Biotech Industry conference on March 29, 2007, at 3:30 p.m.
Eastern Time from Millennium Broadway Hotel in New York City.
Surface Logix Inc. currently has two programs in human clinical trials
with a third program approaching its initial regulatory submission. Mr.
Mahoney will discuss the latest results for SLx-2101, currently in Phase
IIa, a second generation PDE5 inhibitor designed to address cardiovascular
indications, including Raynaud's Syndrome and Hypertension; and SLx-4090,
soon to be in Phase IIa, a first-in-class enterocyte specific MTP inhibitor
targeting unmet needs in dyslipidemia, metabolic disorders and obesity.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to
create new small molecule drugs that are optimized to meet the challenges
of human physiology. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contacts:
Warwick Tong MB ChB
Surface Logix Inc.
Senior Vice President, Commercial Development
617.746.8505
Kari Watson
MacDougall Biomedical Communications Inc.
kwatson@macbiocom.com
508.647.0209
SOURCE Surface Logix Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Warwick Tong MB ChB, Senior Vice President,
Commercial Development, of Surface Logix Inc., +1-617-746-8505;
or Kari Watson, for Surface Logix Inc., +1-508-647-0209, or
kwatson@macbiocom.com
|
